Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
Gemini will undertake a corporate restructuring that will see a drastic 80% of its workforce laid off.
The agreement would have created a spin-off gene therapy company and merged it with ARYA IV to create a new, publicly-traded entity called Caritas Therapies.
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.
Pfizer is cutting its sales staff as physicians and healthcare facilities prefer fewer face-to-face interactions with vendors due to the COVID-19 pandemic.
Daiichi wants to maximize its investment in three antibody-drug conjugates, which the company has positioned as one of the strategic pillars of its 5-year Business Plan.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company's highest-value activities.
When 2022 rolls around in a little more than a week, some Genentech employees will begin the new year in search of a new job.
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company's future growth.
Deciphera Pharmaceuticals announced it is restructuring with the intention of prioritizing clinical development of specific programs and streamlining its commercial operations.
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.